Mylan and Momenta to work on 6 biosimilars; Mylan CFO Sheehan to retire; Ex-Turing CEO Shkreli tapped brokerage account to make $5M bail payment;

@FiercePharma: China Animal Healthcare creates embarrassment for stakeholder Lilly. FierceAnimalHealth story | Follow @FiercePharma

@EricPFierce: ICYMI: 18 months after the FDA slapped Cadila with a Form 483, it sends a warning letter. More | Follow @EricPFierce

@CarlyHFierce: If hospitalized Valeant chief makes an exit, it'll be without a golden parachute. More | Follow @CarlyHFierce

> Momenta Pharmaceuticals ($MNTA) announced deal to work with Mylan on 6 biosimilars. Release

> Mylan ($MYL) says CFO John Sheehan has said he will retire April 1. Release

> Court filings show that former Turing Pharmaceuticals CEO Martin Shkreli tapped a $45 million E*Trade account to make his bail after his arrest on securities charges. Story

> Janus Capital Corp. sold off about $1.5 billion worth of Allergan ($AGN) stock during the last quarter. Report

Medical Device News

@FierceMedDev: Bard to close Minnesota plant, eliminating 185 jobs. Article | Follow @FierceMedDev

@EmilyWFierce: $GSK halting speakers fees for docs in an effort to clean up its tarnished rep. More from the FT | Follow @EmilyWFierce

@VarunSaxena2: ICYMI: NEA partner outlines challenging med tech VC landscape heading into 2016. Article | Follow @VarunSaxena2

> Sony, Fujifilm reportedly considering bidding for Toshiba's $3B+ imaging device unit. More

> Validic app enables remote medical device data capture via smartphone camera. Report

> Michael J. Fox Foundation and Cynapsus team for wearable device study for Parkinson's. Article

Biotech News

@FierceBiotech: Zymeworks bags a $61.5M round, with a merger on tap and an IPO in view. Report | Follow @FierceBiotech

@JohnCFierce: Mylan bets $245M on a 50/50 biosimilar development pact with Momenta. Story | Follow @JohnCFierce

@DamianFierce: I feel like Bill Gross trying to get people to rise up against Bill Gross. More | Follow @DamianFierce

> Moderna's billion-dollar R&D shop partners up to finally enter the clinic. Report

> Sanofi and Regeneron line up for FDA approval with an arthritis treatment. Story

> Mylan bets $245M on a 50/50 biosimilar development pact with Momenta. Article

Suggested Articles

A third spinal muscular atrophy treatment option is set to debut with the FDA’s approval for Roche’s Evrysdi, formerly known as risdiplam.

Already developing coronavirus treatments, Takeda struck a licensing deal to manufacture and market Novavax's vaccine candidate in Japan

Pfizer struck a deal to produce Gilead Sciences' remdesivir, which has been running short at some hard-hit U.S. hospitals.